# Efficacy and Safety of GP40081 Сompared to NovoMix® 30 FlexPen® in Type 2 Diabetes Mellitus Patients

Study · id `cardio:ct-nct04226105` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04226105](<https://clinicaltrials.gov/study/NCT04226105>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04226105

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 264 participants.

## Technical summary

Registry record NCT04226105. Randomized; no masking; primary purpose treatment. Start 2020-01-20 (actual); primary completion 2020-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 264 participants (planned count; ClinicalTrials.gov record NCT04226105, source copy `cardio:ctgov-nct04226105-2020-04-15`, retrieved 2026-10-26)
- Started: 2020-01-20 (actual) (ClinicalTrials.gov record NCT04226105, source copy `cardio:ctgov-nct04226105-2020-04-15`, retrieved 2026-10-26)
- Primary completion: 2020-09-30 (anticipated) (ClinicalTrials.gov record NCT04226105, source copy `cardio:ctgov-nct04226105-2020-04-15`, retrieved 2026-10-26)
- Completion: 2020-12-25 (anticipated) (ClinicalTrials.gov record NCT04226105, source copy `cardio:ctgov-nct04226105-2020-04-15`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT04226105, source copy `cardio:ctgov-nct04226105-2020-04-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04226105-2020-04-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of GP40081 Сompared to NovoMix® 30 FlexPen® in Type 2 Diabetes Mellitus Patients
- Condition: Diabetes Mellitus, Type 2
- Condition: Diabetes Mellitus
- Intervention (Drug): GP40081
- Intervention (Drug): NovoMix 30
- Lead sponsor: Geropharm
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Geropharm (`cardio:org-geropharm`)

## Provenance

Content hash: 21b820952b6dc3c31b9c26cdb3a6a32cb53e2e15bbddb25533938903b0feb23c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
